Subjective cognitive decline domain improves accuracy of plasma Aβ_(42)/Aβ_(40)for preclinical Alzheimer’s disease diagnosis:The SILCODE studyOACSTPCDMEDLINE
To the Editor:Accumulating evidence has shown that the preclinical stage of Alzheimer’s disease(AD)(i.e.,asymptomatic amyloidosis)lasts for decades before the onset of cognitive symptoms,providing a large window for early intervention.Amyloid pathology,the earliest pathological change associated with AD,can be detected in vivo with cerebrospinal fluid(CSF)analysis or positron emission tomography(PET),and its presence is necessary for the diagnosis of preclinical AD(pre-AD).However,both PET scans and CSF analyses are expensive,hampering their use in large-scale screening.Thus,blood-based biomarkers are desirable alternatives,as they are cost-effective and not invasive.
Mingkai Zhang;Xiaoni Wang;Weina Zhao;Yuxia Li;Chao Ying;Jiehui Jiang;Yanning Cai;Jie Lu;Ying Han;
Department of Neurology,Xuanwu Hospital of Capital Medical University,Beijing 100053,ChinaDepartment of Neurology,Sir Run Run Shaw Hospital,Affiliated with School of Medicine,Zhejiang University,Hangzhou,Zhejiang 310016,ChinaDepartment of Neurology,Hongqi Hospital Affiliated to Mudanjiang Medical University,Mudanjiang,Heilongjiang 157011,China Heilongjiang Key Laboratory of Ischemic Stroke Prevention and Treatment,Mudanjiang,Heilongjiang 157011,ChinaDepartment of Neurology,Tangshan Central Hospital,Tangshan,Hebei 063000,ChinaDepartment of Neurobiology,Xuanwu Hospital of Capital Medical University,Key Laboratory for Neurodegenerative Diseases of the Ministry of Education,Beijing 100053,ChinaInstitute for Advanced Communication and Data Science,Shanghai University,Shanghai 200444,ChinaDepartment of Radiology and Nuclear Medicine,Xuanwu Hospital,Capital Medical University,Beijing 100053,China Beijing Key Laboratory of Magnetic Resonance Imaging and Brain Informatics,Beijing 100053,China Key Laboratory of Neurodegenerative Diseases,Ministry of Education,Beijing 100053,ChinaDepartment of Neurology,Xuanwu Hospital of Capital Medical University,Beijing 100053,China School of Biomedical Engineering,Hainan University,Haikou,Hainan 570228,China Center of Alzheimer’s Disease,Beijing Institute for Brain Disorders,Beijing 100053,China National Clinical Research Center for Geriatric Disorders,Beijing 100053,China Institute of Biomedical Engineering,Shenzhen Bay Laboratory,Shenzhen,Guangdong 518132,China
临床医学
diagnosisclinicalAlzheimer
《Chinese Medical Journal》 2024 (009)
P.1127-1129 / 3
supported by grants from the National Natural Science Foundation of China(Nos.82020108013 and 82001773);National Key Research and Development Program of China(No.2022YFC24069004);Beijing Brain Initiative from Beijing Municipal Science&Technology Commission(No.Z201100005520018);STI2030-Major Projects(No.2022ZD0211800)
评论